AROA BIOSURGERY LIMITED Financials Aroa Biosurgery Limited
Equities
ARX
NZARXE0001S1
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5 AUD | +1.01% |
|
-2.91% | -39.76% |
| 04-30 | Transcript : Aroa Biosurgery Limited, Q4 2024 Earnings Call, Apr 30, 2024 | |
| 01-29 | Transcript : Aroa Biosurgery Limited, Q3 2024 Earnings Call, Jan 30, 2024 |
Valuation
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 392.4 | 286.6 | 384.7 | 187.6 | - | - |
| Enterprise Value (EV) 1 | 373.3 | 235.1 | 345.8 | 161 | 158.7 | 154.5 |
| P/E ratio | -20.4 x | -34.2 x | -934 x | -24.9 x | 79.5 x | 13.1 x |
| Yield | - | - | - | - | - | 0.62% |
| Capitalization / Revenue | 17.6 x | 7.22 x | 6.07 x | 2.77 x | 2.15 x | 1.7 x |
| EV / Revenue | 16.7 x | 5.92 x | 5.46 x | 2.38 x | 1.82 x | 1.4 x |
| EV / EBITDA | -83 x | -157 x | 224 x | -61.5 x | 25.5 x | 8.48 x |
| EV / FCF | -59.5 x | -14.7 x | -35.3 x | -12.7 x | -30.2 x | 14.1 x |
| FCF Yield | -1.68% | -6.8% | -2.83% | -7.89% | -3.31% | 7.11% |
| Price to Book | 6.71 x | 2.85 x | 3.78 x | 1.93 x | 1.88 x | 1.64 x |
| Nbr of stocks (in thousands) | 300,726 | 342,461 | 343,109 | 344,208 | - | - |
| Reference price 2 | 1.305 | 0.8370 | 1.121 | 0.5395 | 0.5395 | 0.5395 |
| Announcement Date | 24/05/21 | 23/05/22 | 30/05/23 | - | - | - |
1NZD in Million2NZD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 22.34 | 39.68 | 63.36 | 67.78 | 87.08 | 110.6 |
| EBITDA 1 | -4.498 | -1.497 | 1.542 | -2.618 | 6.217 | 18.21 |
| EBIT 1 | -6.361 | -4.628 | -2.292 | -6.753 | 1.675 | 13.31 |
| Operating Margin | -28.47% | -11.66% | -3.62% | -9.96% | 1.92% | 12.04% |
| Earnings before Tax (EBT) 1 | -19.1 | -8.261 | -0.384 | -5.488 | 2.471 | 14.91 |
| Net income 1 | -19.21 | -8.386 | -0.396 | -6.995 | 2.421 | 13.99 |
| Net margin | -85.98% | -21.13% | -0.62% | -10.32% | 2.78% | 12.65% |
| EPS 2 | -0.0639 | -0.0245 | -0.001200 | -0.0217 | 0.006790 | 0.0412 |
| Free Cash Flow 1 | -6.272 | -15.98 | -9.801 | -12.7 | -5.256 | 10.98 |
| FCF margin | -28.07% | -40.26% | -15.47% | -18.73% | -6.04% | 9.93% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 60.31% |
| FCF Conversion (Net income) | - | - | - | - | - | 78.49% |
| Dividend per Share 2 | - | - | - | - | - | 0.003330 |
| Announcement Date | 24/05/21 | 23/05/22 | 30/05/23 | - | - | - |
1NZD in Million2NZD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.18 | 13.16 | 17.85 | 21.83 | 29.34 | 34.02 | 31.87 | 35.87 |
| EBITDA 1 | -2.316 | -2.182 | -1.156 | -0.341 | 1.319 | 0.223 | -2.667 | -0.196 |
| EBIT 1 | -3.45 | -2.911 | -2.702 | -1.926 | -0.525 | -1.767 | -4.806 | -2.598 |
| Operating Margin | -37.58% | -22.12% | -15.14% | -8.82% | -1.79% | -5.19% | -15.08% | -7.24% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 25/11/20 | 24/05/21 | 24/11/21 | 23/05/22 | 28/11/22 | 30/05/23 | 27/11/23 | - |
1NZD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 19.1 | 51.5 | 38.8 | 26.6 | 28.9 | 33.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -6.27 | -16 | -9.8 | -12.7 | -5.26 | 11 |
| ROE (net income / shareholders' equity) | -22.9% | -6.76% | -0.39% | -6.43% | 2.86% | 9.41% |
| ROA (Net income/ Total Assets) | - | -8.72% | -0.35% | -6.67% | 2.41% | 9.78% |
| Assets 1 | - | 96.16 | 114.6 | 104.9 | 100.3 | 143 |
| Book Value Per Share 2 | 0.1900 | 0.2900 | 0.3000 | 0.2800 | 0.2900 | 0.3300 |
| Cash Flow per Share 2 | -0.0200 | -0.0300 | -0.0100 | -0.0100 | 0 | 0.0300 |
| Capex 1 | 1.27 | 4.46 | 6.03 | 5.13 | 3.6 | 3.6 |
| Capex / Sales | 5.66% | 11.23% | 9.52% | 7.56% | 4.13% | 3.25% |
| Announcement Date | 24/05/21 | 23/05/22 | 30/05/23 | - | - | - |
1NZD in Million2NZD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.5395
NZD
Average target price
1.108
NZD
Spread / Average Target
+105.35%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -39.76% | 114M | |
| +10.10% | 27.85B | |
| -30.22% | 3.09B | |
| +35.19% | 2.66B | |
| -18.85% | 2.44B | |
| +6.85% | 2.24B | |
| +32.22% | 2.05B | |
| -4.71% | 2.02B | |
| +34.05% | 1.35B | |
| +3.33% | 1.33B |
- Stock Market
- Equities
- ARX Stock
- Financials Aroa Biosurgery Limited
